Literature DB >> 18765113

Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.

Matthew R Smith1.   

Abstract

Gonadotropin-releasing hormone (GnRH) agonists are the mainstay of treatment for recurrent and metastatic prostate cancer. GnRH agonists are also an important part of therapy for many men with localized or locally advanced prostate cancer. Although GnRH agonists improve survival in certain settings, they involve adverse effects including vasomotor flushing, obesity, and osteoporosis. This article describes the evidence that GnRH agonists increase risk for diabetes and cardiovascular disease and reviews the potential mechanisms for treatment-related morbidity.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18765113      PMCID： PMC3047401          DOI： 10.1007/s11934-008-0035-y

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


  44 in total

1.  Insulin sensitivity during combined androgen blockade for prostate cancer.

Authors:  Matthew R Smith; Hang Lee; David M Nathan
Journal:  J Clin Endocrinol Metab       Date:  2006-01-24       Impact factor: 5.958

2.  Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia.

Authors:  L M Eri; P Urdal; A G Bechensteen
Journal:  J Urol       Date:  1995-07       Impact factor: 7.450

3.  Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial.

Authors:  M B Garnick
Journal:  Urology       Date:  1986-01       Impact factor: 2.649

Review 4.  Testosterone, body composition and aging.

Authors:  A Vermeulen; S Goemaere; J M Kaufman
Journal:  J Endocrinol Invest       Date:  1999       Impact factor: 4.256

5.  Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.

Authors:  Alfredo Berruti; Luigi Dogliotti; Carlo Terrone; Stefania Cerutti; Giancarlo Isaia; Roberto Tarabuzzi; Giuseppe Reimondo; Mauro Mari; Paola Ardissone; Stefano De Luca; Giuseppe Fasolis; Dario Fontana; Salvatore Rocca Rossetti; Alberto Angeli
Journal:  J Urol       Date:  2002-06       Impact factor: 7.450

6.  The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer.

Authors:  J C Smith; S Bennett; L M Evans; H G Kynaston; M Parmar; M D Mason; J R Cockcroft; M F Scanlon; J S Davies
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

Review 7.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Richard Kahn; John Buse; Ele Ferrannini; Michael Stern
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

8.  Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.

Authors:  M Kusama; K Miyauchi; H Aoyama; M Sano; M Kimura; S Mitsuyama; K Komaki; H Doihara
Journal:  Breast Cancer Res Treat       Date:  2004-11       Impact factor: 4.872

9.  Leuprolide versus diethylstilbestrol for metastatic prostate cancer.

Authors: 
Journal:  N Engl J Med       Date:  1984-11-15       Impact factor: 91.245

10.  Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

Authors:  Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Gerald E Hanks; Miljenko V Pilepich; Howard M Sandler; Matthew R Smith
Journal:  Eur Urol       Date:  2008-01-15       Impact factor: 20.096
View more
  8 in total

1.  Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer.

Authors:  Matthew R Smith; S Bruce Malkowicz; Michael K Brawer; Michael L Hancock; Ronald A Morton; Mitchell S Steiner
Journal:  J Urol       Date:  2011-10-19       Impact factor: 7.450

2.  Androgen deprivation therapy and cataract incidence among elderly prostate cancer patients in the United States.

Authors:  Jennifer Beebe-Dimmer; Hal Morgenstern; Karynsa Cetin; Cecilia Yee; Monina Bartoces; Vahakn Shahinian; Jon Fryzek; John Acquavella; Kendra L Schwartz
Journal:  Ann Epidemiol       Date:  2010-12-15       Impact factor: 3.797

3.  Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.

Authors:  Evan Y Yu; Kevin F Kuo; Roman Gulati; Shu Chen; Teresa E Gambol; Suzanne P Hall; Peter Y Jiang; Peggy Pitzel; Celestia S Higano
Journal:  J Clin Oncol       Date:  2012-04-09       Impact factor: 44.544

Review 4.  Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.

Authors:  Alyssa K Greiman; Thomas E Keane
Journal:  Curr Urol Rep       Date:  2017-06       Impact factor: 3.092

5.  Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer.

Authors:  Matthew R Smith; Laurence Klotz; Bo-Eric Persson; Tine Kold Olesen; Arthur A M Wilde
Journal:  J Urol       Date:  2010-10-16       Impact factor: 7.450

Review 6.  Androgen receptor (AR) in cardiovascular diseases.

Authors:  Chiung-Kuei Huang; Soo Ok Lee; Eugene Chang; Haiyan Pang; Chawnshang Chang
Journal:  J Endocrinol       Date:  2016-01-14       Impact factor: 4.286

Review 7.  Clinical utility of denosumab for treatment of bone loss in men and women.

Authors:  Robert A Adler; Ranjodh S Gill
Journal:  Clin Interv Aging       Date:  2011-05-24       Impact factor: 4.458

8.  A cross-sectional study on gut microbiota in prostate cancer patients with prostatectomy or androgen deprivation therapy.

Authors:  Joseph K M Li; Lynn L Wang; Christine Y P Wong; Peter K F Chiu; Jeremy Y C Teoh; Hilda S W Kwok; Steven C H Leung; Sunny H Wong; Stephen K W Tsui; Chi-Fai Ng
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-04-13       Impact factor: 5.455
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.